Damien Sizaret

Dr. Damien Sizaret


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Carbohydrate Polymers
Verified
Journal Article
Closed access
TCThibault Chazeirat
Thibault Chazeirat
SDSophie Denamur
Sophie Denamur
KBKrzysztof K. Bojarski
Krzysztof K. Bojarski
PAPierre-Marie Andrault
Pierre-Marie Andrault
DSDamien Sizaret
Damien Sizaret
FLFabien Lecaille
Fabien Lecaille

30 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Xavier CansoulineXavier Cansouline
Xavier Cansouline
BLBéatrice Lipan
Béatrice Lipan
DSDamien Sizaret
Damien Sizaret
ATAnne Tallet
Anne Tallet
CVChristophe Vandier
Christophe Vandier
ALAntoine Legras
Antoine Legras
The ADAURA trial has been significant for the perception of EGFR tyrosine kinase inhibitors (TKIs) as a tool for early stage non-small-cell lung cancer (NSCLC). It produced such great insight that the main TKI, Osimertinib, was rapidly integrated into international guidelines for adjuvant use. However, EGFR-mutant NSCLC is a complex entity and has various targeting drugs, and the benefits for patients might not be as clear as they seem. We reviewed trials and meta-analyses considering TKI adjuvant and neoadjuvant use. We also explored the influence of mutation variability and financial evaluations. We found that TKIs often show disease-free survival (DFS) benefits, yet studies have struggled to improve the overall survival (OS); however, the results from the literature might be confusing because of variability in the stages and mutations. The safety profiles and adverse events are acceptable, but costs remain high and accessibility might not be optimal. TKIs are promising drugs that could allow for tailored treatment designs.

21 December 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
PBPaul Bigot
Paul Bigot
SCSimon Chesseron
Simon Chesseron
ASahlame saidi
ahlame saidi
DSDamien Sizaret
Damien Sizaret
CPChristelle Parent
Christelle Parent
GLGilles Lalmanach
Gilles Lalmanach
Background. Chronic obstructive pulmonary disease (COPD) is an irreversible disease mainly caused by smoking. COPD is characterized by emphysema and chronic bronchitis associated with enhanced epithelial permeability. Hypothesis. Lung biopsies from smokers revealed a decreased expression level of occludin, which is a protein involved in the cohesion of epithelial tight junctions. Moreover, the occludin level correlated negatively with smoking history (pack-years), COPD grades, and cathepsin S (CatS) activity. Thus, we examined whether CatS could participate in the modulation of the integrity of human lung epithelial barriers. Methods and results. Cigarette smoke extract (CSE) triggered the upregulation of CatS by THP-1 macrophages through the mTOR/TFEB signaling pathway. In a co-culture model, following the exposure of macrophages to CSE, an enhanced level of permeability of lung epithelial (16HBE and NHBE) cells towards FITC-Dextran was observed, which was associated with a decrease in occludin level. Similar results were obtained using 16HBE and NHBE cells cultured at the air–liquid interface. The treatment of THP-1 macrophages by CatS siRNAs or by a pharmacological inhibitor restored the barrier function of epithelial cells, suggesting that cigarette smoke-elicited CatS induced an alteration of epithelial integrity via the proteolytic injury of occludin. Conclusions. Alongside its noteworthy resistance to oxidative stress induced by cigarette smoke oxidants and its deleterious elastin-degrading potency, CatS may also have a detrimental effect on the barrier function of epithelial cells through the cleavage of occludin. The obtained data emphasize the emerging role of CatS in smoking-related lung diseases and strengthen the relevance of targeting CatS in the treatment of emphysema and COPD.

22 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
XCXavier Cansouline
Xavier Cansouline
AEAbdelhakim Elmraki
Abdelhakim Elmraki
BLBéatrice Lipan
Béatrice Lipan
DSDamien Sizaret
Damien Sizaret
MSMathieu Sordet
Mathieu Sordet
ALAntoine Legras
Antoine Legras
Objective: We explored the impact of uncertain resection in lung cancer on overall survival and disease-free survival. Methods: We performed an exhaustive literature review of all studies comparing prognosis after resection according to the IASLC classification, from the PubMed, Cochrane, MEDLINE, and Google Scholar databases. Results: Overall, 68 original studies were included, of which 67 were retrospective and 1 was prospective, with 81 785 patients included over 46 years. R(un) reclassification was mostly caused by a lack of hilar or mediastinal node dissection, or because of metastasis in the highest node. R(un) is a strong factor for higher recurrence and mortality, while its effects seem limited in early stages. Carcinoma in situ at bronchial margin resection (CIS BRM) does not show an effect on survival, while positive pleural cytology (Cy+) and positive highest mediastinal lymph node (HMLN+) appear to be highly predictive of recurrence and death. Discussion: The R(un) classification of the IASLC appears highly relevant, especially in locally advanced stages IIb-IIIA, and helps to discriminate patients with poor prognosis despite being classified as R0 in the UICC classification. Conclusions: The use of this more precise classification would allow for better stratification of recurrence risk and more effective use of adjuvant therapies. Cy+ patients should receive adjuvant chemotherapy, while CIS BRM patients could likely benefit from endoscopic surveillance to detect local recurrences. HMLN+ patients should be considered at high risk of recurrence, and adjuvant radio-chemotherapy should be considered.


18 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
XCXavier Cansouline
Xavier Cansouline
AEAbdelhakim Elmraki
Abdelhakim Elmraki
BLBéatrice Lipan
Béatrice Lipan
DSDamien Sizaret
Damien Sizaret
SMSordet Mathieu
Sordet Mathieu
ALAntoine Legras
Antoine Legras
Objective: We aimed to explore the relevance of uncertain resection in lung cancer. Methods: We performed an exhaustive literature review of all studies comparing prognosis after resection according to IASLC classification. Results: Systematic review led to select 68 original studies included in this review. R(un) reclassification was mostly caused by a lack of hilar or mediastinal node dissection, or because of metasta-sis in the highest node. R(un) is a strong factor for higher recurrence and mortality, while its effects seem limited in early stages. Carcinoma in situ at bronchial margin resection (CIS BRM) does not show effect on survival, while positive pleural cytology (Cy+) and positive highest mediastinal lymph node (HMLN+) appear to be highly pre-dictive of recurrence and death. Conclusion: The R(un) classification of the IASLC 2005 appears highly relevant, espe-cially in locally advanced stages IIb-IIIA, and helps to discriminate patients with poor prognosis despite being classified as R0 according to UICC classification. The use of this more precise classification would allow for better stratification of recurrence risk and more effective use of adjuvant therapies. Cy+ patients should receive adjuvant chemotherapy, while CIS BRM patients could likely benefit from endoscopic surveil-lance to detect local recurrences. HMLN+ patients should be considered at high risk of recurrence, and adjuvant radiochemotherapy should be considered.